GB2467491A8 - Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies. - Google Patents

Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies. Download PDF

Info

Publication number
GB2467491A8
GB2467491A8 GB201009145A GB201009145A GB2467491A8 GB 2467491 A8 GB2467491 A8 GB 2467491A8 GB 201009145 A GB201009145 A GB 201009145A GB 201009145 A GB201009145 A GB 201009145A GB 2467491 A8 GB2467491 A8 GB 2467491A8
Authority
GB
United Kingdom
Prior art keywords
humanized anti
encephalitis virus
recombinant antibodies
equine encephalitis
venezuelan equine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB201009145A
Other versions
GB2467491A (en
GB201009145D0 (en
GB2467491C (en
GB2467491B (en
Inventor
Hu Wei-Gang
Leslie P Nagata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minister of National Defence of Canada
Original Assignee
Minister of National Defence of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minister of National Defence of Canada filed Critical Minister of National Defence of Canada
Publication of GB201009145D0 publication Critical patent/GB201009145D0/en
Publication of GB2467491A publication Critical patent/GB2467491A/en
Publication of GB2467491A8 publication Critical patent/GB2467491A8/en
Application granted granted Critical
Publication of GB2467491B publication Critical patent/GB2467491B/en
Publication of GB2467491C publication Critical patent/GB2467491C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GB201009145A 2007-11-01 2008-11-03 Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies Expired - Fee Related GB2467491C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002607771A CA2607771A1 (en) 2007-11-01 2007-11-01 Humanized anti-venezuelan equine encephalitis virus recombinant antibody
PCT/CA2008/001940 WO2009055936A1 (en) 2007-11-01 2008-11-03 Humanized anti-venezuelan equine encephalitis virus recombinant antibodies

Publications (5)

Publication Number Publication Date
GB201009145D0 GB201009145D0 (en) 2010-07-14
GB2467491A GB2467491A (en) 2010-08-04
GB2467491A8 true GB2467491A8 (en) 2010-12-22
GB2467491B GB2467491B (en) 2013-03-20
GB2467491C GB2467491C (en) 2013-03-27

Family

ID=40589892

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201009145A Expired - Fee Related GB2467491C (en) 2007-11-01 2008-11-03 Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies

Country Status (3)

Country Link
CA (2) CA2607771A1 (en)
GB (1) GB2467491C (en)
WO (1) WO2009055936A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501157B2 (en) 2007-11-01 2013-08-06 Her Majesty the Queen in right of Canada as represented by The Ministry of National Defence Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies
GB0916630D0 (en) * 2009-09-22 2009-11-04 Secr Defence Antibody
EP3281954A1 (en) 2010-11-04 2018-02-14 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
EP3326649B1 (en) 2012-05-03 2022-02-09 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
WO2016036918A1 (en) 2014-09-03 2016-03-10 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
TWI787942B (en) * 2015-06-24 2022-12-21 日商Ｊｃｒ製藥股份有限公司 Anti-human transferrin receptor antibody that passes through blood-brain barrier
US11130815B2 (en) 2015-06-24 2021-09-28 Jcr Pharmaceuticals Co., Ltd. Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody
CN107586335B (en) * 2016-07-06 2020-12-29 中国科学院微生物研究所 Humanized monoclonal antibody and application
EA201991577A1 (en) 2016-12-26 2019-12-30 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. NEW ANTIBODIES AGAINST THE HUMAN TRANSFERRIN RECEPTOR, ABLE TO BREAK THE HEMATOENCEPHALIC BARRIER

Also Published As

Publication number Publication date
GB2467491A (en) 2010-08-04
CA2607771A1 (en) 2009-05-01
WO2009055936A1 (en) 2009-05-07
GB201009145D0 (en) 2010-07-14
CA2704119C (en) 2014-12-30
GB2467491C (en) 2013-03-27
GB2467491B (en) 2013-03-20
CA2704119A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
GB2467491A8 (en) Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies.
HRP20180873T1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
HRP20150176T1 (en) Anti-myostatin antibodies
AP2011005719A0 (en) Anti-IGF antibodies.
HK1144440A1 (en) Hepatitis c virus antibodies
BRPI0912285A2 (en) monoclonal antibodies having homosubtype cross-neutralizing properties against the h1 subtype influenza virus.
HK1133018A1 (en) Anti-myostatin antibodies
IL214996A (en) Isolated antibody that binds a bmca polypeptide, a pharmaceutical composition comprising the same and uses thereof
EP2304440A4 (en) Novel monoclonal antibodies against hpv proteins
AP2010005332A0 (en) Humanized antibodies specific for von willebrand factor.
IL210493A0 (en) Chimeric respiratory syncytial virus polypeptide antigens
IL236236A (en) Fam26f polypeptide antibodies
HK1154251A1 (en) Humanized antibodies against human interferon alpha
EP2399934A4 (en) Novel monoclonal antibody, and use thereof
IL199974A0 (en) Humanized antibodies against cxcr3
EP2004685A4 (en) Hepatitis c virus neutralizing antibodies
HK1164345A1 (en) Truncated cd20 protein, deltacd20 cd20 deltacd20
PL387291A1 (en) Method of detection of antibodies directed against HPV-11 virus, using the HPV11-L1 heterologic protein
AU2007900058A0 (en) Recombinant Antibodies

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20191103